Atossa Genetics completes enrollment, dosing in Phase 1 trial of Endoxifen
Atossa Genetics announced that all participant activities have been completed in its Phase 1 clinical trial of a new proprietary modified-release oral tablet form of its Endoxifen. This is the next generation of oral Endoxifen following the successful clinical studies of the capsule form of the company's oral Endoxifen. The Phase 1 study is being conducted in Australia. The objectives of the study are to assess safety and tolerability and to ascertain the pharmacokinetics of the tablet. The study is randomized, double-blinded and placebo-controlled with both single and multiple-doses in two groups with a total of 24 healthy female volunteers. Atossa's oral Endoxifen capsule served as the comparator.